Boston Scientific Launches Sirolimus-Based Drug-Coated Balloons in U.S.
What happened
Boston Scientific launched its AGENT, a sirolimus-based drug-coated balloon (DCB), in the U.S. market on October 21, 2026. This device delivers sirolimus to the vessel wall without requiring an additional metal stent. The product enters the market alongside established paclitaxel-based technologies used by interventional cardiologists to treat in-stent restenosis (ISR).
From dicardiology.com
Why it matters
The introduction of this new technology provides alternative options for treating ISR. The report notes that the availability of different drug-coated balloon technologies raises questions about how each option fits into current treatment guidelines and which patients may benefit most from the various approaches.
From dicardiology.com
Who's involved
- Boston ScientificManufacturer of the new sirolimus-based drug-coated balloon
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Stryker CorporationSpeculative
Stryker Corporation might face increased market pressure on revenue in ISR treatment.
- Abbott LaboratoriesSpeculative
Abbott Laboratories might face increased market pressure on revenue in ISR treatment.
- Medtronic plcSpeculative
Medtronic plc might face increased market pressure on revenue in ISR treatment.
- McKesson CorporationSpeculative
McKesson Corporation might see increased volume for medical devices due to demand from Boston Scientific.
Keep exploring
The entities involved
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices